| Disabled Face Hard Health Choices With state budgets shrinking and Medicaid costs climbing rapidly, many states are taking a hard look at cutting home health care for the developmentally disabled. online.wsj.com |
Panelist Who Backed Avandia Gets Fees From Glaxo One of the panelists who voted in favor of the diabetes drug Avandia at an FDA advisory meeting last week is a paid speaker for the drug's maker, Glaxo. online.wsj.com |
Protecting your skin from sun damage - Video An Industry-First Campaign to Educate Tour Players & Fans on Prevention and Treatment of Sun Damage Including Fraxel’s re:store Laser Technology feedproxy.google.com |
PPD Opens Office in Novosibirsk, Russia [Business Wire] - WILMINGTON, N.C.----PPD, Inc. today announced it has opened an office in Novosibirsk, Russia, building on the growth of its Phase II-IV clinical development services in Eastern Europe. us.rd.yahoo.com |
One More Reason Lilly Must Do a Deal, Fast Pharmalot submits: The surprising news released Tuesday night that the FDA has refused to approve the Bydureon diabetes drug - which involves a three-way partnership between Eli Lilly (LLY), Alkermes (ALKS) and Amylin Pharmaceutical (AMLN) - adds tremendous pressure to the big drugmaker to pursue some kind of deal to bolster its anemic pipeline. An acquistion would be the likeliest approach, but Lilly may be more vulnerable bait itself. The initial reaction among some Wall Street wags is that Lilly may want to take a stake in, if not acquire, Amylin, given that so much has already been invested in Bydureon, which the FDA rejected over concerns of cardiac abnormalities. The med, which is a once-weekly version of Byetta, was already delayed due to cancer risks, but Lilly has a long-standing diabetes franchise, and a similar drug in its labs has not proven any better.Complete Story » seekingalpha.com |